Tissue-specific human neuronal calcium channel subtypes and their use

Abstract:

Disclosed are overlapping cDNA sequences encoding for a human voltage-dependent neuronal calcium channel. The complete cDNA which encodes a voltage-operated calcium channel (VOCC) sub-type is assembled from overlapping lambda phages by means of suitable restriction cleavage sites and cloned into a eukaryotic expression vector.

Citations

5386025 5429921

Suggestions

If you were to search for Tissue-specific human neuronal calcium channel subtypes and their use using relaxed search criteria, these patents would come up:

Patent number	Title	Issue date
6200566	Anti-endoglin monoclonal antibodies and their use in antiangiogenic therapy	2001-03-13
6200606	Isolation of precursor cells from hematopoietic and nonhematopoietic tissues and their use in vivo bone and cartilage regeneration	2001-03-13
6200645	Polyester resin impregnating and coating solutions and their use	2001-03-13
6200750	Mammalian homologous recombination activating sequences and method of identification and their use thereof	2001-03-13
6200931	5,6-dihydro-(1,4,2)-Dioxazin-substituted (hetero) aryl-(oxy-, imino-, alkyl-)-sulphonylamino(thio)carbonyl-heterocyclyl derivatives, their preparation and their use as herbicides	2001-03-13
6200935	Arylalkyltriazole derivatives and their use as herbicides	2001-03-13
6200936	Salicyclic calixarenes and their use as lubricant additives	2001-03-13
6200970	2,3-benzodiazepine derivatives and their use as AMPA-receptor inhibitors	2001-03-13
6200997	Heterocyclyl-substituted phenyl compounds, processes and intermediates for their preparation and their use for controlling harmful fungi and animal pests	2001-03-13
6201004	Dioxino derivatives and their use as therapeutic agents	2001-03-13
6201027	Substituted .beta. diketones and their use	2001-03-13
6201115	Amplifying sequences, vectors comprising these sequences and their uses in compositions for the expression of nucleotide sequences in transfected cells therapeutic and vaccine applications	2001-03-13
6201129	Tricyclic derivatives and their use as anti-cancer agents	2001-03-13
6204044	Human parvovirus B19 proteins and virus-like particles, their production and their use in diagnostic assays and vaccines	2001-03-20
6204053	Porcine cortical cells and their use in treatment of neurological deficits due to neurodegenerative diseases	2001-03-20
6204238	Fatty acid derivatives and their use as surfactants in detergents and cleaners	2001-03-20
6204306	Functionalized photoinitiators, derivatives and macromers therefrom and their use	2001-03-20
6207173	Lysine derivatives containing an N.epsilon.-alkoxy or N.epsilon.-alkenoxycarbonyl group, their preparation and their use in cosmetic, pharmaceutical, hygiene or food compositions	2001-03-27
6229000	Tissue-specific human neuronal calcium channel subtypes and their use	2001-05-08
6284774	4-Benzyl piperidine alkylsulfoxide heterocycles and their use as subtype-selective NMDA receptor antagonists	2001-09-04

Claims:

We claim:

1. An isolated and purified DNA sequence comprising a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 2-5, 9-14 and 16.

2. The isolated and purified DNA sequence according to claim 1, which comprises a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 12 and 13.

3. The isolated and purified DNA sequence according to claim 1, which comprises a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 3, 9 and 14.

4. The isolated and purified DNA sequence according to claim 1, which comprises a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 4 and 16.

5. The isolated and purified DNA sequence according to claim 1, which comprises a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 5 and 11.

6. The isolated and purified DNA sequence according to claim 1, which comprises a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 2 and 10.

7. An isolated and purified DNA sequence selected from the group consisting of SEQ ID NOS.: 2-5, 9-14 and 16.

Patent number:
6229000
View patent at USPTO

Filing date:
May 31, 1995

Issue date:
May 8, 2001

Inventors:
Jurgen Franz (Haan, DE)
Peter Rae (West Haven, CT)
Axel Unterbeck (West Haven, CT)
Bernhard Weingartner (Wuelfrath, DE)

Assignee:
Bayer Aktiengesellschaft (Leverkusen, DE)

Primary Examiner:
Anthony C. Caputa

Assistant Examiner:
Stephen Gucker

Attorney, Agent or Firm:
Sprung Kramer Schaefer & Briscoe

Current U.S. Classification: 536/23.1 536/23.5 536/24.1 536/24.3 536/24.31